Imugene US /
Precision BioSciences, Inc.
Imugene US acquires Precision BioSciences manufacturing infrastructure
What happened
Imugene US acquired Precision BioSciences, Inc.’s CAR T manufacturing infrastructure and related assets, including facility lease, equipment, supplies and clinical trial inventory.
Precision will receive upfront economics valued at $21 million, consisting of cash and equity, for global rights to azer-cel and the infrastructure and experienced cell therapy teams.
The source
Everything on this page comes from the source below.
Imugene US acquires Precision BioSciences manufacturing infrastructure
This document is the source for the companies, stage, figure and people on this page.
Original filingUnlock with ProTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Published by the source
The source this page is built from.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request accessAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly